ECSP014054A - Activadores de glucoquinasa alquinil fenil heteroaromatica - Google Patents

Activadores de glucoquinasa alquinil fenil heteroaromatica

Info

Publication number
ECSP014054A
ECSP014054A EC2001004054A ECSP014054A ECSP014054A EC SP014054 A ECSP014054 A EC SP014054A EC 2001004054 A EC2001004054 A EC 2001004054A EC SP014054 A ECSP014054 A EC SP014054A EC SP014054 A ECSP014054 A EC SP014054A
Authority
EC
Ecuador
Prior art keywords
heteroaromatica
glucoquinase
alquinil
fenil
activities
Prior art date
Application number
EC2001004054A
Other languages
English (en)
Inventor
Paige Ering Mahaney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP014054A publication Critical patent/ECSP014054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las para - alquinil fenil amidas heteroaromáticas que son activas como activadores de la glucoquinasa para incrementar la secreción de insulina lo cual las hace útiles en el tratamiento de la diabetes tipo II.
EC2001004054A 2000-05-03 2001-05-03 Activadores de glucoquinasa alquinil fenil heteroaromatica ECSP014054A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20154600P 2000-05-03 2000-05-03

Publications (1)

Publication Number Publication Date
ECSP014054A true ECSP014054A (es) 2002-01-25

Family

ID=22746271

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001004054A ECSP014054A (es) 2000-05-03 2001-05-03 Activadores de glucoquinasa alquinil fenil heteroaromatica

Country Status (18)

Country Link
US (1) US6388071B2 (es)
EP (1) EP1282612B1 (es)
JP (1) JP3788935B2 (es)
KR (1) KR100502033B1 (es)
CN (1) CN1176915C (es)
AR (1) AR032453A1 (es)
AT (1) ATE286036T1 (es)
AU (2) AU2001270494B2 (es)
BR (1) BR0110573A (es)
CA (1) CA2407416C (es)
DE (1) DE60108108T2 (es)
EC (1) ECSP014054A (es)
ES (1) ES2233660T3 (es)
MX (1) MXPA02010745A (es)
PE (1) PE20011310A1 (es)
PT (1) PT1282612E (es)
WO (1) WO2001083465A2 (es)
ZA (1) ZA200208542B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
GB2409678B (en) * 2001-12-19 2005-09-21 Hoffmann La Roche Crystals of glucokinase and methods of growing them and ligands of glucokinase
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
DE60336850D1 (en) * 2003-01-06 2011-06-01 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
KR20070007104A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
BRPI0507746A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
EP1824835A1 (en) * 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
KR101346902B1 (ko) * 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
WO2007026761A1 (ja) 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007125105A2 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
KR20090025358A (ko) 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 글루코키나제 활성화제로서의 피라졸
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
KR20090090390A (ko) * 2006-12-21 2009-08-25 아스트라제네카 아베 Ｇｌｋ 활성제로서 유용한 신규 결정 화합물
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CA2679185A1 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
JP5248477B2 (ja) * 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
JP5287730B2 (ja) 2008-01-18 2013-09-11 アステラス製薬株式会社 フェニルアセトアミド誘導体
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
EP2324028A2 (en) 2008-08-04 2011-05-25 AstraZeneca AB Therapeutic agents 414
UA104742C2 (uk) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2014035872A1 (en) * 2012-08-27 2014-03-06 Amgen Inc. Tricyclic alkynes that interact with glucokinase regulatory protein
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
EP3053834B1 (en) 2015-02-04 2019-03-27 Tetra Laval Holdings & Finance S.A. Forming assembly and method for forming a plurality of sealed packs for pourable food products starting from a tube of packaging material
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61115054A (ja) * 1984-11-08 1986-06-02 Taisho Pharmaceut Co Ltd スチレンアルカン酸誘導体
WO1996040113A2 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
ES2198719T3 (es) * 1997-06-24 2004-02-01 Zeria Pharmaceutical Co., Ltd. Procedimiento de produccion de los derivados de 2-hidroxibenzamida.

Also Published As

Publication number Publication date
PT1282612E (pt) 2005-04-29
US20010053851A1 (en) 2001-12-20
AU2001270494B2 (en) 2005-11-10
CN1432004A (zh) 2003-07-23
AU7049401A (en) 2001-11-12
KR20020093117A (ko) 2002-12-12
CN1176915C (zh) 2004-11-24
EP1282612A2 (en) 2003-02-12
CA2407416A1 (en) 2001-11-08
AR032453A1 (es) 2003-11-12
DE60108108T2 (de) 2005-12-08
JP2003531898A (ja) 2003-10-28
DE60108108D1 (de) 2005-02-03
ATE286036T1 (de) 2005-01-15
EP1282612B1 (en) 2004-12-29
BR0110573A (pt) 2003-04-01
KR100502033B1 (ko) 2005-07-25
MXPA02010745A (es) 2003-03-10
CA2407416C (en) 2006-07-18
JP3788935B2 (ja) 2006-06-21
WO2001083465A2 (en) 2001-11-08
PE20011310A1 (es) 2001-12-31
US6388071B2 (en) 2002-05-14
ZA200208542B (en) 2004-01-22
WO2001083465A3 (en) 2002-05-16
ES2233660T3 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
UY26694A1 (es) Activadores de fenil glucocinasa para - arilo o hetero sustituidos
PA8584001A1 (es) Indol-3-carboxamidas como activadores de glucoquinasa (gk)
ECSP014055A (es) Activadores de glucoquinasa que contienen hidantoina
PA8534601A1 (es) Activadores de glucocinasa del tipo isoindolin-1-ona
ECSP014062A (es) Activadores de fenilamida glucoquinasa para-amina sustituida
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
ATE494280T1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl- bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
CO6351786A2 (es) Inkibidores de la cinasa map p38
ECSP066894A (es) Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
GT200500113A (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
GB0326633D0 (en) Therapeutic agents
AR036174A1 (es) Tratamiento para la piel
MXPA05004133A (es) Nuevos compuestos antitumorales.
UY26690A1 (es) Activadores heteroaromáticos de la alquinil - fenil glucoquinasa
DK1893237T3 (da) Farmaceutisk sammensætning, der omfatter en organopolysiloxan ela-stomer og et solubiliseret aktivt stof
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.